282 related articles for article (PubMed ID: 25141341)
1. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
Bhat R; Tummalapalli SR; Rotella DP
J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
[TBL] [Abstract][Full Text] [Related]
2. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
4. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
5. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
6. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
Kitson RR; Moody CJ
Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
[TBL] [Abstract][Full Text] [Related]
7. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
8. Structure-based and in silico design of Hsp90 inhibitors.
Sgobba M; Rastelli G
ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
[TBL] [Abstract][Full Text] [Related]
9. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
11. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
15. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
16. Protein chaperones as anticancer therapy targets.
Sausville E
Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
[No Abstract] [Full Text] [Related]
17. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
Wang Y; McAlpine SR
Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]